Respiratory Clinical Trial Recruitment
Respiratory trials demand speed, precision, and strong demographic reach—especially in conditions where timing, geography, and symptom progression directly impact enrollment success. Studies for COPD, asthma, ILD/IPF, pulmonary hypertension, sleep apnea, RSV, flu, COVID-19, and pneumonia face challenges ranging from narrow I/E criteria to short seasonal windows.
Challenges include:
- Patients with long histories of respiratory disease who may feel discouraged or overwhelmed.
- Eligibility tied to symptom timing, chronic disease patterns, or seasonal surges.
- Comorbidities such as cardiovascular disease, obesity, or smoking history that influence qualification.
- Communities disproportionately affected by chronic respiratory illness but historically underrepresented in research.
For sponsors, CROs, and sites, these realities frequently lead to extended enrollment timelines and inconsistent referral flow.
OmniCRS is a proven partner in effectively reaching and engaging individuals interested in respiratory research, with experience generating large volumes of leads, including 44,000+ respiratory-related leads reflected in past campaign outputs.
Results That Move Respiratory Trials Forward
OmniCRS brings the scale and consistency needed to support both high-demand acute studies and longer-cycle chronic respiratory programs. With 44,000+ leads generated across respiratory indications in previous campaigns, we understand the nuances of engaging these populations.
OmniCRS has supported respiratory recruitment efforts across both chronic and acute studies, generating tens of thousands of leads and enabling sponsors and CROs to build predictable early enrollment momentum.
Our work helps clinical teams:
- Increase awareness among individuals affected by chronic respiratory disease.
- Reach high-intent audiences during seasonal peaks or periods of elevated public interest.
- Improve participant understanding of what a clinical trial may involve—within recruitment-only limits.
- Strengthen demographic reach across communities often underrepresented in pulmonary research.
These advantages support faster, more reliable enrollment for respiratory studies without adding burden to site operations.
Our Impact in Respiratory Recruitment
With more than 832,000 engaged patients, 35+ therapeutic areas, and the proven scalability to deliver thousands of leads per study when needed, OmniCRS brings unmatched reach and consistency to respiratory programs.
Strong pre-screening conversion
High participant responsiveness
Early-stage targeting
Inclusive outreach
Predictable recruitment velocity
How We Deliver Exceptional Respiratory Recruitment
OmniCRS’ model is built to improve the quality and predictability of referrals for dermatology trials—while staying compliant, focused, and within our recruitment scope
- Performance-driven outreach: Our campaigns connect with respiratory patients across diverse digital environments, from search and social channels to condition-aligned communities. Messaging is tailored to reflect how respiratory symptoms or chronic disease experiences may resonate with potential participants.
- Targeted interest segmentation: Using audience signals tied to respiratory health journeys such as chronic respiratory symptoms, past diagnoses, or educational content behavior, we build campaigns that help attract individuals more likely to recognize themselves in the study description.
- Inclusive strategies for broader enrollment Respiratory disease disproportionately affects certain communities. OmniCRS uses multilingual and culturally aligned creative to reach individuals across diverse backgrounds, supporting more inclusive respiratory research participation
Proprietary fraud-prevention
HIPAA / GDPR / FDA compliance
Continuous quality monitoring
Partner With OmniCRS to Advance Respiratory Research
Respiratory trials require scale, consistency, and sensitivity to patient experience. OmniCRS delivers high-intent referrals grounded in compliance and supported by a robust marketing engine helping sponsors, CROs, and sites move respiratory therapies forward with confidence.